ClinicalTrials.gg
Active, not recruitingNCT06532344Updated Oct 7, 2026

An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic Cancer

A Phase 1 interventional study of ONO-7913 and ONO-4538 in Metastatic Pancreatic Cancer, sponsored by Ono Pharmaceutical Co., Ltd.. Active, not recruiting at 9 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Ono Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 11 months after the study started (first participant enrolled Jul 2021, registered Jul 2024).
Updated Oct 7, 2026Primary completion movedStudy completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 93 studies in Pancreatic Neoplasms with a site in Japan — 17 open to participants now, 34 under way, 8 of them phase 3. Pancreatic Neoplasms · Japan.

Enrollment
68th of 84
32 · median 120
Started
2021
with 5 others
Phase 1
25 of 93
3 open now
Primary completion
2027-06
later than 13 of 33 live
Registered
78th of 93
by date

Among the 93 studies in Pancreatic Neoplasms with a site in Japan, this one is the 68th largest by enrollment of the 84 interventional ones that give a count, is one of 6 that started in 2021, is one of 25 in phase 1, reaches primary completion later than 13 of the 33 other live ones, and was the 78th registered.

Pancreatic Neoplasms

3,902 studies on the registry are indexed under Pancreatic Neoplasms; 1,004 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

17 of the 93 studies in Pancreatic Neoplasms with a site in Japan are open now. Recruiting first, the newest first:

12 more — sign in →

All 17 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 741 Pancreatic Neoplasms studies recruiting now, 475 (64%) set no upper age limit and 152 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 93 studies in Pancreatic Neoplasms with a site in Japan, or all of them as a file.
02

Study summary

To investigate the tolerability and safety of ONO-7913 and ONO-4538 used in combination with modified FOLFIRINOX (mFFX therapy), the standard of care, as first-line treatment in patients with metastatic pancreatic cancer.

03

Conditions studied

  • Metastatic Pancreatic Cancer
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Untreated pancreatic cancer
  • 2. of at least 3 months
  • 3. Patients with performance status 0 or 1

Exclusion criteria

Exclusion Criteria:

  • 1. Patients with severe complication
  • 2. Patients with multiple primary cancers
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    ONO-7913+ONO-4538+mFFX

    Drug: ONO-7913 · Drug: ONO-4538 · Drug: Oxaliplatin · Drug: Levofolinate · Drug: Irinotecan · Drug: Fluorouracil

Interventions

  • Specified dose on specified days

    Also known as: Magrolimab

  • Specified dose on specified days

    Also known as: Nivolumab

  • Specified dose on specified days

  • Specified dose on specified days

  • Specified dose on specified days

  • Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Dose-limiting toxicities(DLT)

    Time frame: 28 days

  2. Adverse event(AE)

    Time frame: UP to 30 days after the last dose

Secondary outcomes

  1. Pharmacokinetics(serum concentration of ONO-7913)

    Time frame: Through study completion, an average of 6 months

  2. Pharmacokinetics(serum concentration of ONO-4538)

    Time frame: Through study completion, an average of 6 months

  3. Overall response rate (ORR)

    Time frame: Through study completion, an average of 6 months

  4. Disease control rate (DCR)

    Time frame: Through study completion, an average of 6 months

  5. Overall survival (OS)

    Time frame: Through study completion, an average of 6 months

  6. Progression-free survival (PFS)

    Time frame: Through study completion, an average of 6 months

  7. Duration of response (DOR)

    Time frame: Through study completion, an average of 6 months

  8. Time to response (TTR)

    Time frame: Through study completion, an average of 6 months

  9. Best overall response (BOR)

    Time frame: Through study completion, an average of 6 months

  10. Percentage of change in the sum of tumor diameters of target lesions

    Time frame: Through study completion, an average of 6 months

  11. Maximum percentage of change in the sum of tumor diameters of target lesions

    Time frame: Through study completion, an average of 6 months

  12. Changes in tumor markers (CEA and CA19-9)

    Time frame: Through study completion, an average of 6 months

07

Study locations

9 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2021 (actual). Primary completion is estimated for Jun 2027, 71 months after the start.

Of 172 industry-sponsored phase 1 interventional studies under Pancreatic Neoplasms, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 62. This study's planned 71 months is above that.

Counting every sponsor, half of 381 studies reached it within 45 months; a quarter within 32 and three quarters within 68.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 7, 2026: primary completion Dec 2026 → Jun 2027 and completion Dec 2026 → Jun 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2024
First posted
Aug 1, 2024
StartActual
Jul 30, 2021
Primary completionEst.
Jun 30, 2027was Dec 2026
CompletionEst.
Jun 30, 2027was Dec 2026
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added, 3 sites removed
Show 3 added (3 Japan)
  • Kanagawa Cancer Center · Yokohama, Japan
  • Seirei Hamamatsu General Hospital · Hamamatsu, Japan
  • National Cancer Center Hospital · Chūōku, Japan
Show 3 removed
  • Kanagawa Cancer Center · Yokohama-shi, Japan
  • Seirei Hamamatsu General Hospital · Hamamatsu-shi, Japan
  • National Cancer Center Hospital · Chuo Ku, Japan
Oct 7, 2026
Primary completion
Dec 31, 2026→Jun 30, 2027
Oct 7, 2026
Study completion
Dec 31, 2026→Jun 30, 2027
Oct 7, 2026
Sponsor
Ono Pharmaceutical Co. Ltd→Ono Pharmaceutical Co., Ltd.
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    3 sites added, 3 sites removed
    Show 3 added (3 Japan)
    • Kanagawa Cancer Center · Yokohama, Japan
    • Seirei Hamamatsu General Hospital · Hamamatsu, Japan
    • National Cancer Center Hospital · Chūōku, Japan
    Show 3 removed
    • Kanagawa Cancer Center · Yokohama-shi, Japan
    • Seirei Hamamatsu General Hospital · Hamamatsu-shi, Japan
    • National Cancer Center Hospital · Chuo Ku, Japan
    Primary completion Dec 31, 2026→Jun 30, 2027
    Study completion Dec 31, 2026→Jun 30, 2027
    Sponsor Ono Pharmaceutical Co. Ltd→Ono Pharmaceutical Co., Ltd.
    + 5 other changes: identifiers, verification date, criteria formatting, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06532344
Responsible party
Sponsor
First posted
Aug 1, 2024
Start date
Jul 30, 2021
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Oct 7, 2026

Study contacts

Project Leader
study director · Ono Pharmaceutical Co., Ltd.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Magrolimab

Start the discussion